Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference
Rhea-AI Summary
Fractyl Health (Nasdaq: GUTS) will report first quarter 2026 financial results and provide business updates on May 12, 2026 at 4:30 p.m. ET. A live webcast and archived replay will be available in the company’s Events section at http://ir.fractyl.com.
CEO Harith Rajagopalan, M.D., Ph.D. will present at the BofA Securities 2026 Health Care Conference on May 14, 2026 at 9:20 a.m. PT (12:20 p.m. ET); that presentation will also be webcast and archived.
Positive
- None.
Negative
- None.
News Market Reaction – GUTS
In the May 5 session, GUTS declined 4.57%, reflecting a moderate negative market reaction. Argus tracked a trough of -4.2% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 24 | Earnings and updates | Positive | +16.2% | Q4 and 2025 results with clinical progress and runway into early 2027. |
| Mar 17 | Earnings date set | Neutral | -0.2% | Scheduled Q4 and full-year 2025 earnings call and webcast details. |
| Feb 26 | Trial milestone | Positive | -6.2% | Completion of REMAIN-1 pivotal randomization and reiterated Q4 2026 data timing. |
| Jan 29 | Clinical data update | Positive | -68.0% | Positive 6‑month REMAIN‑1 midpoint data for Revita after GLP‑1 discontinuation. |
| Jan 06 | Leadership change | Positive | -2.9% | Appointment of new CFO to support commercial-stage preparedness. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Stock has often sold off on positive clinical and corporate updates, with only the full-year 2025 earnings release showing a clear positive alignment.
Over the past months, Fractyl Health has focused on advancing Revita and preparing for commercialization. On Jan 29, strong six‑month REMAIN‑1 midpoint data coincided with a -68.04% move. Completion of pivotal randomization and reiteration of cash runway into early 2027 on Feb 26 saw a -6.19% reaction. In contrast, Q4 and full-year 2025 results on Mar 24 aligned with a 16.17% rise. The prior earnings date announcement on Mar 17 had minimal impact, suggesting today’s scheduling news may be a secondary catalyst relative to major data or results releases.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will report financial results for the first quarter 2026 and provide business updates on Tuesday, May 12, 2026, at 4:30 p.m. ET.
A live webcast of the conference call and presentation can be accessed in the “Events” section of Fractyl Health’s website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event.
The Company also announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of Fractyl Health, will present at the BofA Securities 2026 Health Care Conference on Thursday, May 14, 2026, at 9:20 a.m. PT (12:20 p.m. ET).
A live webcast of the presentation can be accessed in the “Events” section of Fractyl Health’s website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event.
About Fractyl Health
Fractyl Health is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes. Our Revita® and Rejuva® candidates are designed to target root causes of metabolic diseases, allowing us to advance metabolic disease treatment from chronic management towards prevention and reversal of disease. Fractyl is headquartered in Burlington, Massachusetts.
Contact
Brian Luque, Head of Investor Relations and Corporate Development
IR@fractyl.com, 951.206.1200
